We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+82%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$209M
AUM Growth
+$44M
Cap. Flow
-$21.4M
Cap. Flow %
-10.24%
Top 10 Hldgs %
42.68%
Holding
94
New
26
Increased
5
Reduced
16
Closed
34

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$5.81M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.8M
3
ELVN icon
Enliven Therapeutics
ELVN
+$4.43M
4
WVE icon
Wave Life Sciences
WVE
+$4.28M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$4.06M

Top Sells

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$8.17M
2
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$4.16M
3
ETNB
89bio
ETNB
+$4.02M
4
COGT icon
Cogent Biosciences
COGT
+$3.88M
5
APGE icon
Apogee Therapeutics
APGE
+$3.75M

Sector Composition

Rank Sector Weight
1 Healthcare 96.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
76
PUT
Liquidia Corp
LQDA
$7.48B
– –
-53,000
Closed -$1.21M
MLTX icon
77
MoonLake Immunotherapeutics
MLTX
$1.57B
– –
-178,084
Closed -$1.28M
NVO
78
CALL
Novo Nordisk
NVO
$208B
– –
-35,000
Closed -$1.94M
ORIC icon
79
Oric Pharmaceuticals
ORIC
$1.15B
– –
-120,644
Closed -$1.45M
PPH icon
80
CALL
VanEck Pharmaceutical ETF
PPH
$959M
– –
-30,000
Closed -$2.71M
PRAX icon
81
CALL
Praxis Precision Medicines
PRAX
$8.58B
– –
-10,000
Closed -$530K
PRCT icon
82
Procept Biorobotics
PRCT
$1.06B
– –
-39,900
Closed -$1.42M
QURE icon
83
uniQure
QURE
$3.03B
– –
-22,090
Closed -$1.29M
REPL icon
84
Replimune Group
REPL
$941M
– –
-73,614
Closed -$308K
SLNO
85
DELISTED
Soleno Therapeutics
SLNO
– –
-48,445
Closed -$2.66M
SNDX icon
86
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-117,783
Closed -$1.81M
TVTX icon
87
CALL
Travere Therapeutics
TVTX
$5.2B
– –
-110,000
Closed -$2.63M
VTYX
88
DELISTED
Ventyx Biosciences
VTYX
– –
-60,600
Closed -$188K
ATYR
89
CALL
aTyr Pharma
ATYR
$47.6M
– –
-40,000
Closed -$28.8K
MBX
90
CALL
MBX Biosciences
MBX
$3.14B
– –
-30,000
Closed -$525K
MBX
91
MBX Biosciences
MBX
$3.14B
– –
-52,402
Closed -$917K
MBX
92
PUT
MBX Biosciences
MBX
$3.14B
– –
-50,500
Closed -$884K
1 2 3
4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
CA
Carson Advisory Athens, Georgia $193M AUM 14.52% 1-Year Est. Return

Exome Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, Exome Asset Management held 94 positions worth $209M, up 27% from $165M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Exome Asset Management withdrew a net $21.4M in Q4 2025, closing 34 positions and reducing 16 holdings. Its most notable exit was 89bio, an estimated $4.02M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier.

Against the trend, Exome Asset Management opened a new position in Elevance Health worth $6.03M.

  • Exome Asset Management's largest Q4 2025 buy was Elevance Health: 17,191 shares worth $6.03M.
  • Exome Asset Management added most to Universal Health Services in Q4 2025, an estimated $2.14M increase.
  • Exome Asset Management's biggest Q4 2025 reduction was Praxis Precision Medicines, cutting an estimated $8.17M.
  • Exome Asset Management fully exited 89bio in Q4 2025, selling an estimated $4.02M.
  • Exome Asset Management's ten largest holdings make up 43% of its $209M portfolio in Q4 2025.
  • Exome Asset Management opened 26 new positions and closed 34 in Q4 2025.
  • Exome Asset Management's portfolio value rose 27% quarter-over-quarter to $209M.

Based on Exome Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.